← back to search

Michael G. Schlossmacher

National Institute of Neurological Disorders and Stroke · US
Area of research
Neurology · Cellular and Molecular Neuroscience
Research interest
Research interests include Disease, Parkinson's disease, Medicine, Neurology, Alpha-synuclein, and Cerebrospinal fluid.
h-index
citations
649
works
9
NIH funding
primary concept
email

Recent publications

Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis
Nature Reviews Neurology 2024cited by 23position: middledoi
Defining the Riddle in Order to Solve It: There Is More Than One “Parkinson's Disease”
Movement Disorders 2023cited by 45position: middledoi
Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
npj Parkinson s Disease 2021cited by 176position: middledoi
Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites
Acta Neuropathologica 2021cited by 58position: lastdoi
Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease
Journal of Neuroinflammation 2017cited by 104position: middledoi
Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects
Journal of Neural Transmission 2017cited by 68position: lastdoi
Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders
Journal of Neurochemistry 2015cited by 75position: lastdoi
α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system
Journal of Neural Transmission 2012cited by 72position: lastdoi
Mutant <i>GBA1</i> Expression and Synucleinopathy Risk: First Insights from Cellular and Mouse Models
Neurodegenerative Diseases 2012cited by 28position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Brit Mollenhauer · Short and Associates (United States)5 papers (2012–2023)Tiago F. Outeiro · Newcastle University2 papers (2021–2023) · 2 papers (2017–2021) · 2 papers (2017–2021)Leonidas Stefanis · Nagoya University of Arts2 papers (2021–2023)Jianjun Chang · Emory University1 papers (2017–2017)Ian G. McKeith · Newcastle Hospitals - Campus for Ageing and Vitality1 papers (2023–2023)George T. Kannarkat · University of Pennsylvania1 papers (2017–2017)Hermona Soreq · Hebrew University of Jerusalem1 papers (2023–2023) · 1 papers (2021–2021)Angela Nguyen · Sinai Health System1 papers (2017–2017)Malú G. Tansey · Indiana University Health1 papers (2017–2017)Marcel M. Verbeek · Radboud University Nijmegen1 papers (2015–2015)Larry Ereshefsky · The University of Texas at San Antonio1 papers (2017–2017) · 1 papers (2015–2015)Francisco Cardoso · University of Colorado Denver1 papers (2023–2023) · 1 papers (2021–2021) · 1 papers (2017–2017)S. Pablo Sardi · Sanofi (United States)1 papers (2012–2012)Joaquim J. Ferreira · University of Antwerp1 papers (2023–2023)